What’s Going to Be Hot at TCT 2026

To be held in San Diego, CA, this year’s meeting offers 28 late-breaking studies, hands-on training, in-person connection, and more.

What’s Going to Be Hot at TCT 2026

Transcatheter Cardiovascular Therapeutics, known colloquially as TCT, is set to return this year to San Diego, CA, for the second time in its 38-year history.

TCT 2026, the top US meeting for interventional cardiovascular medicine, kicks off on Saturday, October 31, with ample opportunities to experience the latest in research, hands-on training, and in-person connections over 4 days.

The entire TCTMD news team will be on-site at the San Diego Convention Center to share the best of TCT 2026. You’ll be able to find all our articles here as soon as they’re posted. And don’t forget our videos! Expect new episodes of Beyond the Data with Senior Clinical Editor Mamas Mamas, BMBCh, DPhil, as well as On Record and Cardialogue.

On a recent episode of TCTMD’s Rox Heart Radio podcast, Roxana Mehran, MD (Icahn School of Medicine at Mount Sinai, New York, NY), welcomed two guests to preview what’s to come in San Diego: Juan Granada, MD, CEO of the Cardiovascular Research Foundation, and Martin Leon, MD, founder and director of TCT.

Asked to highlight one thing that attendees “absolutely should not miss” at TCT 2026, Leon highlighted Monday as whole. 

“Monday is the day that we’re going to be showing some of the best clinical trials that we’ve ever presented at TCT. [These] undoubtedly are going to be practice-changing,” he said. That day “gives us an opportunity to be able to think in a very creative way about where we’ve been, what we’ve done, and where we’re going. And where we’re going in interventional cardiology really is defined by what happens at TCT, and it’s not entirely predictable.”

Granada, for his part, said that Saturday’s MedTech Innovation Forum is special this year. Its sessions will feature “structured but not scripted” discussions with leaders in the field, he noted. 

Also compelling are the changes in cardiology sparked by artificial intelligence (AI), which will receive special focus at TCT 2026 both in the meeting’s AI Lab and in other sessions, he added. “This is going to be the year in which the upslope of the inflection point is going to start, because the impact that AI is having in our field is as scary as exciting. It’s transformational, and we’re taking this very seriously.” 

Using the metaphor of a triangle, Granada said the issues posed by AI can be visualized on three sides: the value of continuing to use best practices when caring for patients, the ways that AI is already changing the practice of medicine, and the need to “form the leaders of the future and not lose the humanity, which is the most important thing right now.”

TCT as a whole offers “amazing programs [and] amazing science,” he added. “The central message is: let’s get united during these transformational times and let’s not forget the basic principles of our specialty.”

Saturday’s start to the meeting involves not only the MedTech Innovation Forum but also the Nurse and Technologist Symposium, cases with the masters, featured clinical research, and sessions devoted to best practices. A mix of topical discussions, research presentations, live cases, and other content such as the AI Lab and 3R: Regulatory, Research, and Reimbursement sessions come over the next 3 days. Continuing traditions include the Master Operator Award, Career Achievement Award, Linnemeier Award, and Shark Tank competition.

This year’s special speaker is Jason Sudeikis, the award-winning actor, comedian, writer, and producer, who will explore “leadership, resilience, teamwork, and the power of human connection” on Monday, November 2, at 11:15 AM in the Main Arena.

For attendees seeking the latest data on interventional cardiology—both structural and coronary—the late-breaking clinical trial (LBCT) and late-breaking clinical science (LBCS) sessions no doubt will be of interest. Here’s the rundown of what’s expected.

Sunday, November 1

Sunday’s LBCT session, held in collaboration with the Lancet, features randomized trials focused on the coronary space. These include P4, which compares coronary CT angiography and IVUS for PCI guidance, as well as the TRANSFORM II trial of sirolimus-coated Magic Touch balloons (Concept Medical) versus everolimus-eluting stents in native coronary vessels. HD-PCI compares higher- and lower-dose heparin for PCI, while the sham-controlled REMEDY-PILOT explores the feasibility and efficacy of the Shockwave Reducer (Shockwave Medical), a coronary sinus reducer, in the setting of angina with nonobstructive coronary arteries.

The LBCS session held that afternoon, in collaboration with Circulation, encompasses a wide range of structural heart research, including real-world insights on tricuspid regurgitation (TR), the TRAVEL III trial of transcatheter tricuspid valve replacement with the LuX-Valve Plus system (Jenscare Scientific) versus medical therapy for severe TR, and what will hopefully be a revealing look at key subgroup results of the TRIC-I-HF-DZHK24 trial, whose main results on transcatheter tricuspid valve intervention were released during this year’s European Society of Cardiology Congress. Additionally, 1-year outcomes of the VERITAS study on the Amulet 360 device (Abbott) for left atrial appendage occlusion (LAAO) will be presented, as will economic and cost-effectiveness data from the EARLY TAVR trial of asymptomatic severe aortic stenosis.

Monday, November 2

Next up in the late-breaking lineup, on Monday, is an LBCT session held in cooperation with the New England Journal of Medicine. This one features structural topics as well, with data on the aortic, mitral, and tricuspid valves and on LAAO. First comes the PROGRESS randomized trial, pitting TAVI with Sapien 3/Sapien 3 Ultra/Sapien 3 Ultra Resilia (Edwards Lifesciences) against clinical surveillance for moderate AS. The session is set to include a 30-year perspective on degenerative mitral valve disease from the Global Burden of Disease study, as well as clinical and health status findings from the CLASP II TR trial of transcatheter tricuspid valve repair with Pascal (Edwards Lifesciences) versus medical therapy. Finally, there will be the SIMPLAAFY triple-arm randomized trial of aspirin only, reduced-dose direct oral anticoagulant, or dual antiplatelet therapy following LAAO with the Watchman FLX Pro (Boston Scientific).

An LBCS session held together with the European Heart Journal is set to take place in the afternoon. Among its offerings are two randomized trials in peripheral artery disease: one involves 1-year outcomes for the PeriSorb bioresorbable vascular scaffold (AMT Medical) compared with drug-coated balloons for superficial femoral artery disease and the other provides 3-year outcomes from the SIRONA trial of Magic Touch sirolimus-coated balloons versus paclitaxel-coated ballons for femoropopliteal artery disease. In the coronary space, an analysis of the AIR-STEMI randomized trial, which released main results at ESC 2026, will assess the impact of nonculprit lesion severity when using functional coronary angiography to gauge physiology in STEMI patients with multivessel disease. The LIPSIA-STRATEGY trial also delves into the potential of angiography-derived fractional flow reserve (FFR) to guide coronary revascularization, comparing it to traditional wire-based FFR. And to wrap things up, there will be a trial looking at intracoronary delivery of the vasodilator nicorandil as a means to prevent no-reflow in STEMI patients undergoing primary PCI.

Tuesday, November 3

On the final day of the meeting, two late-breaking sessions will take place.

The morning features an LBCT session, held in collaboration with JACC, covering a mix of subspecialties. The first presentation is on PIONEER IV, a trial testing angiography-derived FFR compared with usual care in all-comers PCI. The EPIC17-VERONICA trial, up next, will provide new data on VerifyNow (Werfen) platelet function testing to guide de-escalation of P2Y12 inhibitors after acute coronary syndromes. Additionally, there’s the SPYRAL AFFIRM postapproval study of radiofrequency renal denervation with Simplicity Spyral (Medtronic) in the United States as well as a look at long-term survival in the IRIS-MAIN registry of patients undergoing revascularization for unprotected left main disease. In the TAVI space, the session’s final trial compares access-site closure after transfemoral cases with single versus double Perclose ProGlide devices (Abbott).

To wrap up TCT 2026, the afternoon LBCS session, in collaboration with JAMA, includes structural-focused presentations. First, there’s 2-year data from the ENCIRCLE trial of percutaneous transcatheter mitral valve replacement with Sapien M3 (Edwards Lifesciences) in symptomatic mitral regurgitation. Final results from the PROTEMBO IDE trial of the ProtEmbo cerebral protection system (Protembis) in TAVI will follow. Three studies relate to aortic regurgitation (AR)—these are the JENA-VAD study of TAVI with JenaValve Trilogy (JenaValve Technology) in patients with a left ventricular assist device, the randomized DUOTAP trial of routine postdilatation versus conventional deployment during balloon-expandable TAVI, and 1-year results from a randomized trial that compares transcatheter and surgical AVR for symptomatic, severe AR.

* * *

Drop by the press room during TCT to say hi! Reach out with any ideas, inspirations, or feedback via email.

Caitlin E. Cox is Executive Editor of TCTMD and Associate Director, Editorial Content at the Cardiovascular Research Foundation. She produces the…

Read Full Bio

Comments